Clinical Trials Directory

Trials / Unknown

UnknownNCT02260739

Sequential Analysis in Patients With an Hemopathy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
246 (estimated)
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Recent advances in hematology clearly illustrate that the simple "clonal" nature of various hematological malignancies may not really reflect the reality of malignant cells natural expansion. This has been nicely illustrated in recent works in AML for example where subclones coexists in the same patient at the same time, but could also differentially expand over time because of effects of therapeutics intervention, but also by oncogenic spontaneous events (1). These observations have been done recently because of next generation sequencing that allows to discriminate in the same tumor samples, different subclones and to analyse the clonal architecture. Sequential analyses could help us to identify the first oncogenic event and to correlate disease progression to the emergence of subclones. For all these reasons it is of a major interest to precisely understand the architecture of the clone in MPNs, especially to understand which is the initiating event and how from this initial event the clone develops. In MPNs in which JAK2V617F is the initiating event, its targeting is expected to be extremely effective. If JAK2V617F is a secondary event its targeting might allow to alleviate the MPN, but may favor the development of other malignant hemopathies.

Conditions

Interventions

TypeNameDescription
OTHERBlood samples

Timeline

Start date
2014-01-01
Primary completion
2019-01-01
Completion
2026-01-01
First posted
2014-10-09
Last updated
2017-08-08

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02260739. Inclusion in this directory is not an endorsement.